Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | PRCP | P42785 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | F10 | P00742 | 5/20 | 0.54 |
| ▸ | PREP | P48147 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8750799 | 0.88 | NPSR1 (0.55) | NPSR1HDAC8PRCPPTPN1F10 | |
| SCHEMBL7038189 | 0.84 | PREP (0.50) | NPSR1PREPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL9033817 | 0.84 | HDAC8 (0.64) | HDAC8PTPN1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL9033831 | 0.84 | HDAC8 (0.64) | HDAC8PTPN1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL7038648 | 0.83 | KDM4E (0.62) | PRCPKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1061148 | 0.82 | NPSR1 (0.60) | NPSR1HDAC8PTPN1F10PREP | |
| SCHEMBL9572242 | 0.82 | NPSR1 (0.64) | NPSR1HDAC8PTPN1F10KDM4E | |
| SCHEMBL9572243 | 0.82 | NPSR1 (0.64) | NPSR1HDAC8PTPN1F10KDM4E | |
| SCHEMBL6244596 | 0.81 | PRCP (0.57) | HDAC8PRCPKDM4ECYP3A4 | |
| SCHEMBL7038658 | 0.81 | PRCP (0.57) | HDAC8PRCPKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | INSERM | 2003-02-06 | — | — | US | disclosed |
| US-6403561-B1 | DISORDERS ASSOCIATED WITH THE INACTIVATION OR EXCESSIVE DEGRADATION OF CHOLECYSTOKININ; INHIBITING THE ENZYMATIC HYDROLYSIS OF CHOLECYSTOKININ 1-(2(S)-AMINOBUTYRYL)-2(S)-INDOLINECARBOXYLIC ACID | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | DPP4, DPP3, DPP9 | NPSR1 397/4885HDAC8 1425/4885PRCP 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.